Articles by Jill Wechsler - Pharmaceutical Executive

ADVERTISEMENT

Articles by Jill Wechsler

Jill Wechsler

Washington Editor

Jill Wechsler is the Washington Editor for Pharmaceutical Executive and writes about federal government policies and programs that affect the pharmaceutical industry. Her monthly Washington Report discusses legislative proposals, FDA initiatives and actions by other government agencies, including Medicare pharmacy benefit proposals, federal investigations related to pharmaceutical company marketing, debate over DTC advertising, generic drug competition, over-the-counter initiatives, among other topics. She has written for PE for more than ten years and also covers Washington for other Advanstar publications, including Pharmaceutical Technology, Applied Clinical Trials, BioPharm, Managed Healthcare Executive and Formulary. Prior to that she reported on government policies and a wide range of topics for business and consumer publications.

Articles
Obama Policies Reshape Pharma Marketing
April 10, 2014

Health reform initiatives promote transparency, challenge reimbursement, writes Jill Wechsler.

Manufacturers Struggle with FDA's "Breakthrough Drug" Development
March 21, 2014

Accelerated testing and production create challenges in documenting product quality, writes Jill Wechsler.

Data disclosure, integrity challenge pharma
March 1, 2014

Transparency initiatives are multiplying, affecting research, marketing and compliance.

The Push for Transparency: Risks, Costs, and Concerns
February 26, 2014

The growing clamor for broader access to information on health care practices, policies and costs is affecting research, marketing and compliance, writes Jill Wechsler.

Drug Coverage, Costs Under Scrutiny
February 1, 2014

Benefits offered by insurance plans on health exchanges and through Medicare are raising concerns about patient access to needed therapies, writes Jill Wechsler.

US Pharma Challenges 2014
January 8, 2014

Pricing and personalized medicine are key themes shaping drug development and marketing in the U.S. in 2014, writes Jill Wechsler.

Pharma Challenges for 2014
January 1, 2014

Pricing and personalized medicine are key themes shaping drug development and marketing

FDA Pursues Delicate Balancing Act
December 1, 2013

The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler.

Clinical Trial Sponsors Struggle with Data Disclosure Requirements
November 25, 2013

Research sponsors argue that widening access to patient level data from clinical trials will undermine patient privacy and incentives for new drug development.

ADVERTISEMENT

Click here